The new cancer research, published in The Lancet Oncology journal, examined the levels of circulating tumor DNA (ctDNA) found in cancer patients' blood. Approximately 80% of stage 3 melanoma ...

The study, published in Journal of Hematology & Oncology, offers a thorough analysis of recent advancements in ctDNA detection methods and their clinical significance. Lymphoma, a complex ...

Approximately 25% of patients had ctDNA- or imaging-confirmed recurrence. More than 30% had evidence of recurrence by imaging that ctDNA did not identify. The addition of serial circulating tumor ...

Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the study showed that approximately 80 percent of stage 3 melanoma patients who had detectable levels of circulating tumor ...

The project, led by Friends of Cancer Research, aims to establish whether ctDNA fluctuations can predict patient responses to therapy. Initial results linked ctDNA changes with overall survival in ...

(23) Research has demonstrated the clinical prognostic value of ctDNA in a variety of cancer types both before and after treatment (4). Despite this potential the adoption of ctDNA testing remains ...

CSF-ctDNA was detected in 59% of cases and showed high concordance (84%) with tumor mutations. Lower variant allelic frequency in CSF-ctDNA was associated with significantly worse survival outcomes.

We are also thrilled that NeXT Personal results from the TRACERx collaboration, one of the largest ctDNA studies in early-stage lung cancer, will be presented at the meeting," said Dr. Richard ...

(2,3) Research has demonstrated the clinical prognostic value of ctDNA in a variety of cancer types both before and after treatment (4). Despite this potential, the adoption of ctDNA testing ...